326 related articles for article (PubMed ID: 29105104)
1. B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury.
Faggioli F; Palagano E; Di Tommaso L; Donadon M; Marrella V; Recordati C; Mantero S; Villa A; Vezzoni P; Cassani B
Hepatology; 2018 May; 67(5):1970-1985. PubMed ID: 29105104
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
3. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
[TBL] [Abstract][Full Text] [Related]
4. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
5. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer.
Philips GM; Chan IS; Swiderska M; Schroder VT; Guy C; Karaca GF; Moylan C; Venkatraman T; Feuerlein S; Syn WK; Jung Y; Witek RP; Choi S; Michelotti GA; Rangwala F; Merkle E; Lascola C; Diehl AM
PLoS One; 2011; 6(9):e23943. PubMed ID: 21912653
[TBL] [Abstract][Full Text] [Related]
6. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis.
Potikha T; Stoyanov E; Pappo O; Frolov A; Mizrahi L; Olam D; Shnitzer-Perlman T; Weiss I; Barashi N; Peled A; Sass G; Tiegs G; Poirier F; Rabinovich GA; Galun E; Goldenberg D
Hepatology; 2013 Jul; 58(1):192-204. PubMed ID: 23423643
[TBL] [Abstract][Full Text] [Related]
7. Deletion of tumour necrosis factor α receptor 1 elicits an increased TH17 immune response in the chronically inflamed liver.
Berkhout L; Barikbin R; Schiller B; Ravichandran G; Krech T; Neumann K; Sass G; Tiegs G
Sci Rep; 2019 Mar; 9(1):4232. PubMed ID: 30862875
[TBL] [Abstract][Full Text] [Related]
8. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
Schneider C; Teufel A; Yevsa T; Staib F; Hohmeyer A; Walenda G; Zimmermann HW; Vucur M; Huss S; Gassler N; Wasmuth HE; Lira SA; Zender L; Luedde T; Trautwein C; Tacke F
Gut; 2012 Dec; 61(12):1733-43. PubMed ID: 22267597
[TBL] [Abstract][Full Text] [Related]
9. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.
Lin H; Yan J; Wang Z; Hua F; Yu J; Sun W; Li K; Liu H; Yang H; Lv Q; Xue J; Hu ZW
Hepatology; 2013 Jan; 57(1):171-82. PubMed ID: 22859216
[TBL] [Abstract][Full Text] [Related]
10. Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2
Zhou T; Wu N; Meng F; Venter J; Giang TK; Francis H; Kyritsi K; Wu C; Franchitto A; Alvaro D; Marzioni M; Onori P; Mancinelli R; Gaudio E; Glaser S; Alpini G
Lab Invest; 2018 Nov; 98(11):1449-1464. PubMed ID: 29977037
[TBL] [Abstract][Full Text] [Related]
11. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte IKK2 protects Mdr2-/- mice from chronic liver failure.
Ehlken H; Kondylis V; Heinrichsdorff J; Ochoa-Callejero L; Roskams T; Pasparakis M
PLoS One; 2011; 6(10):e25942. PubMed ID: 22022477
[TBL] [Abstract][Full Text] [Related]
13. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
[TBL] [Abstract][Full Text] [Related]
14. Functional role of CCL5/RANTES for HCC progression during chronic liver disease.
Mohs A; Kuttkat N; Reißing J; Zimmermann HW; Sonntag R; Proudfoot A; Youssef SA; de Bruin A; Cubero FJ; Trautwein C
J Hepatol; 2017 Apr; 66(4):743-753. PubMed ID: 28011329
[TBL] [Abstract][Full Text] [Related]
15. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
Ma C; Kesarwala AH; Eggert T; Medina-Echeverz J; Kleiner DE; Jin P; Stroncek DF; Terabe M; Kapoor V; ElGindi M; Han M; Thornton AM; Zhang H; Egger M; Luo J; Felsher DW; McVicar DW; Weber A; Heikenwalder M; Greten TF
Nature; 2016 Mar; 531(7593):253-7. PubMed ID: 26934227
[TBL] [Abstract][Full Text] [Related]
16. Early heme oxygenase 1 induction delays tumour initiation and enhances DNA damage repair in liver macrophages of Mdr2
Barikbin R; Berkhout L; Bolik J; Schmidt-Arras D; Ernst T; Ittrich H; Adam G; Parplys A; Casar C; Krech T; Karimi K; Sass G; Tiegs G
Sci Rep; 2018 Nov; 8(1):16238. PubMed ID: 30389969
[TBL] [Abstract][Full Text] [Related]
17. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice.
Barashi N; Weiss ID; Wald O; Wald H; Beider K; Abraham M; Klein S; Goldenberg D; Axelrod J; Pikarsky E; Abramovitch R; Zeira E; Galun E; Peled A
Hepatology; 2013 Sep; 58(3):1021-30. PubMed ID: 23526353
[TBL] [Abstract][Full Text] [Related]
18. Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model.
Potikha T; Pappo O; Mizrahi L; Olam D; Maller SM; Rabinovich GA; Galun E; Goldenberg DS
FASEB J; 2019 Jul; 33(7):7995-8007. PubMed ID: 30897344
[TBL] [Abstract][Full Text] [Related]
19. The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma.
Gamaev L; Mizrahi L; Friehmann T; Rosenberg N; Pappo O; Olam D; Zeira E; Bahar Halpern K; Caruso S; Zucman-Rossi J; Axelrod JH; Galun E; Goldenberg DS
Oncogene; 2021 Jan; 40(1):127-139. PubMed ID: 33093654
[TBL] [Abstract][Full Text] [Related]
20. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
Wan Y; Meng F; Wu N; Zhou T; Venter J; Francis H; Kennedy L; Glaser T; Bernuzzi F; Invernizzi P; Glaser S; Huang Q; Alpini G
Hepatology; 2017 Aug; 66(2):528-541. PubMed ID: 28256736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
